Adjuvant denosumab in early breast cancer
- PMID: 32135106
- DOI: 10.1016/S1470-2045(20)30019-X
Adjuvant denosumab in early breast cancer
Comment in
-
Adjuvant denosumab in early breast-cancer.Lancet Oncol. 2020 Mar;21(3):e123. doi: 10.1016/S1470-2045(20)30057-7. Lancet Oncol. 2020. PMID: 32135107 No abstract available.
-
Adjuvant denosumab in early breast-cancer.Lancet Oncol. 2020 Mar;21(3):e124. doi: 10.1016/S1470-2045(20)30066-8. Lancet Oncol. 2020. PMID: 32135108 No abstract available.
-
Adjuvant denosumab in early breast cancer - Authors' reply.Lancet Oncol. 2020 Mar;21(3):e125. doi: 10.1016/S1470-2045(20)30099-1. Lancet Oncol. 2020. PMID: 32135109 No abstract available.
Comment on
-
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.Lancet Oncol. 2020 Jan;21(1):60-72. doi: 10.1016/S1470-2045(19)30687-4. Epub 2019 Dec 2. Lancet Oncol. 2020. PMID: 31806543 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
